UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000035607
Receipt number R000040556
Scientific Title Discovering immune complex antigen specific for oral cancer in saliva
Date of disclosure of the study information 2019/02/01
Last modified on 2021/06/14 10:04:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Discovering immune complex antigen specific for oral cancer in saliva

Acronym

Immune complex antigens in oral cancer

Scientific Title

Discovering immune complex antigen specific for oral cancer in saliva

Scientific Title:Acronym

Immune complex antigens in oral cancer

Region

Japan


Condition

Condition

oral cancer

Classification by specialty

Oral surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

We aim to find immune complex antigens specifically found in saliva of the patients with oral cancer by immune complexome analysis where nano-liquid chromatography-tandem mass spectrometry is employed to comprehensively identify antigens incorporated into immunme complexes in biological fluids.

Basic objectives2

Others

Basic objectives -Others

Clinical Chemistry

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

We analyze immune complex in saliva and identify antigen protein that is not recognized in patients with xerostomia and is specifically detected in oral cancer patients. In addition, we investigate whether specific ones of the antigen proteins are characteristic of patients who have cervical lymph node metastasis or distant metastasis.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. License date of the chief of the research institution - March 31, 2021, a hospital participating in Oral Surgery at Nagasaki University Hospital and Japan Oral Oncology Group (NPO) patient.
2. Target diseases: patients with oral cancer and patients with xerostomia (the standard of xerostomia is 2 g / 2 minutes or less in Saxon test saliva secretion)
3. Age: over 20 years old
4. Gender: male / female
5. Patient who obtained written agreement with the free will of the research subject himself after sufficient explanation for participation in this research.

Key exclusion criteria

1. Patients who are judged inappropriate as researchers by the researchers.

Target sample size

210


Research contact person

Name of lead principal investigator

1st name Kaname
Middle name
Last name Ohyama

Organization

Nagasaki University

Division name

Graduate School of Biomedical Sciences

Zip code

852-8588

Address

Sakamoto 1-7-1, Nagasaki

TEL

095-819-8569

Email

k-ohyama@nagasaki-u.ac.jp


Public contact

Name of contact person

1st name Kaname
Middle name
Last name Ohyama

Organization

Nagasaki University

Division name

Graduate School of Biomedical Sciences

Zip code

852-8588

Address

Sakamoto 1-7-1, Nagasaki

TEL

095-819-8569

Homepage URL


Email

k-ohyama@nagasaki-u.ac.jp


Sponsor or person

Institute

Nagasaki University

Institute

Department

Personal name



Funding Source

Organization

Nagasaki University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor

Japan Oral Oncology Group

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nagasaki University Hospital Clinical Research Ethics Committee

Address

1-7-1 Sakamoto, Nagasaki-shi, Nagasaki-ken

Tel

095-819-7200

Email

gaibushikin@ml.nagasaki-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

長崎大学病院(長崎県)、日本口腔がん臨床研究グループ参加病院


Other administrative information

Date of disclosure of the study information

2019 Year 02 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2018 Year 09 Month 11 Day

Date of IRB

2018 Year 09 Month 11 Day

Anticipated trial start date

2018 Year 09 Month 11 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Presence of disease specific immune complex antigens


Management information

Registered date

2019 Year 01 Month 21 Day

Last modified on

2021 Year 06 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040556


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name